Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT / 9:00 p.m. ET CAMBRIDGE, Mass., Dec. 09,…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and…
December 06, 2024 16:35 ET | Source: BioAge Labs, Inc. Decision follows observations of liver transaminitis without clinically significant symptoms…
December 05, 2024 18:00 ET | Source: MediciNova, Inc. LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc.,…
December 03, 2024 16:05 ET | Source: Beyond Air™ The Phase 1b study will evaluate LV UNO in unresectable cutaneous…
HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced…
SINGAPORE, Dec. 2, 2024 /PRNewswire/ -- George Clinical, a leading global clinical research organisation, is pleased to announce the appointment…
November 26, 2024 03:00 ET | Source: Anocca AB Application to the European Medicines Agency (EMA) covers ANOC-001 as the…
FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule,…
-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities…